Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 7:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 514 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: BOOST Plus Clear all
Completed Phase 2 Interventional Results available

Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas

NCT00100802
View directory record Official record
Conditions
Anaplastic Astrocytoma, Central Nervous System Neoplasm, Glioblastoma, Gliosarcoma, Spinal Cord Neoplasm
Interventions
Laboratory Biomarker Analysis, Lomustine, Radiation Therapy, Temozolomide
Other · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 18, 2026, 7:34 AM EDT
Completed Phase 1 Interventional

Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL)

NCT03269422
View directory record Official record
Conditions
Prostate Cancer
Interventions
MR-based image-guided, intensity-modulated radiotherapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 18, 2026, 7:34 AM EDT
Completed Phase 3 Interventional

Prospective Trial of Two Prone Breast Radiotherapy Techniques With Randomization to Concurrent Versus Weekly Boost

NCT01591811
View directory record Official record
Conditions
Breast Cancer
Interventions
Arm 1 Daily Boost of Radiation Therapy, Arm 2 Weekly Boost of Radiation Therapy
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 18, 2026, 7:34 AM EDT
Completed Early Phase 1 Interventional

Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer

NCT03162731
View directory record Official record
Conditions
Larynx, Lip, Oral Cavity and Pharynx
Interventions
Nivolumab, Ipilimumab, Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy
Biological · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 18, 2026, 7:34 AM EDT
Completed Phase 2 Interventional Results available

Image-Guided Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Shoulder, Arm, Hip, or Leg

NCT00589121
View directory record Official record
Conditions
Lymphedema, Musculoskeletal Complications, Radiation Fibrosis, Radiation Toxicity, Sarcoma
Interventions
Chemotherapy, Radiation therapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
14
States / cities
Newark, Delaware • Gainesville, Florida • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 18, 2026, 7:34 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases

NCT00587964
View directory record Official record
Conditions
Brain Metastasis, Bladder Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, HEENT Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma, Testicular Cancer
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 18, 2026, 7:34 AM EDT
Completed Phase 1 Interventional

Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

NCT00006107
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Taxotere, Surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 18, 2026, 7:34 AM EDT
Recruiting Not applicable Interventional

Harm Reduction for Smokers With Mental Illness

NCT06543407
View directory record Official record
Conditions
Tobacco Dependence
Interventions
SWITCH IT, E-cig Provision Only
Behavioral · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Louisville, Kentucky • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 18, 2026, 7:34 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes

NCT02398383
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis Related Diabetes
Interventions
Oral Glucose Tolerance Test, Mixed Meal Tolerance Test, Hypoglycemic Clamp
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 18, 2026, 7:34 AM EDT
Completed Phase 2 Interventional

Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer

NCT00054301
View directory record Official record
Conditions
Breast Cancer
Interventions
adjuvant therapy, conventional surgery, intraoperative radiation therapy
Procedure · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 18, 2026, 7:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cannabis Edibles Packaging Descriptors Experiment

NCT06171399
View directory record Official record
Conditions
Cannabis Use
Interventions
"All Natural" descriptor, "Gluten-free" descriptor, "Vegan" descriptor, "100% Organic" descriptor, "Handcrafted" descriptor, "Made with live resin" descriptor, "Fast-acting" descriptor, "Relax" descriptor, "Energy Boost" descriptor, No descriptor (control)
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
2,521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 18, 2026, 7:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults

NCT03942406
View directory record Official record
Conditions
Pertussis, Whooping Cough
Interventions
BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device
Combination Product
Lead sponsor
ILiAD Biotechnologies
Industry
Eligibility
18 Years to 50 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Cleveland, Ohio • Tomball, Texas • West Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 18, 2026, 7:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults

NCT00574600
View directory record Official record
Conditions
HIV Infections
Interventions
SAAVI DNA-C2 vaccine, SAAVI MVA-C vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 18, 2026, 7:34 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine

NCT05293665
View directory record Official record
Conditions
COVID-19 Vaccines
Interventions
UB-612, BNT162b2 vaccine, ChAdOx1-S vaccine, Sinopharm BIBP
Biological
Lead sponsor
Vaxxinity, Inc.
Industry
Eligibility
16 Years and older
Enrollment
944 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brownsville, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 18, 2026, 7:34 AM EDT
Recruiting Early Phase 1 Interventional

A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

NCT07017816
View directory record Official record
Conditions
CNS Malignancies, Medulloblastoma Recurrent, ATRT Recurrent, Pineoblastoma, Embryonal Neoplasm, Ependymoma Recurrent, High Grade Gliomas
Interventions
SGT-53, hypofractionated radiotherapy with immunotherapy, Nivolumab
Drug · Radiation
Lead sponsor
Children's National Research Institute
Other
Eligibility
3 Years to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 18, 2026, 7:34 AM EDT
Completed Phase 1 Interventional

A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART

NCT01378156
View directory record Official record
Conditions
HIV-1 Infection
Interventions
JS7 plasmid DNA and MVA62B vaccine
Biological
Lead sponsor
GeoVax, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 18, 2026, 7:34 AM EDT
Recruiting Not applicable Interventional

Adding Spatially Fractionated Radiation Therapy to Standard Palliative Radiation for Improving Disease-Related Symptoms in Patients With Unresectable Solid Tumors

NCT07856394
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm, Unresectable Solid Tumor, Malignant Tumor, Metastatic Solid Tumor
Interventions
Electronic Health Record Review, External Beam Radiation Therapy, Questionnaire Administration, Spatially-fractionated Radiation Therapy
Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
15 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 18, 2026, 7:34 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Fall Prevention Pathways

NCT07824141
View directory record Official record
Conditions
Old Age; Debility
Interventions
The Fall Prevention Pathway (FPP)
Behavioral
Lead sponsor
Emory University
Other
Eligibility
65 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 18, 2026, 7:34 AM EDT
Completed Not applicable Interventional Results available

Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203)

NCT01856855
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Radiation Toxicity, Sexual Dysfunction
Interventions
Stereotactic Body Radiation Therapy with Integrated Boost
Radiation
Lead sponsor
John Fiveash, MD
Other
Eligibility
19 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 18, 2026, 7:34 AM EDT
Completed Phase 3 Interventional Results available

Providing Free Nicotine Patches to Quitline Smokers

NCT01736085
View directory record Official record
Conditions
Smoking Cessation
Interventions
Telephone counseling, Voucher, Nicotine patches
Behavioral · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
3,706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 18, 2026, 7:34 AM EDT
Recruiting Phase 2 Interventional

Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma

NCT05301283
View directory record Official record
Conditions
High Grade Sarcoma
Interventions
Intensity Modulated Radiation Therapy (IMRT), MRI
Radiation · Diagnostic Test
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 18, 2026, 7:34 AM EDT
Completed Phase 2 Interventional Results available

Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer

NCT04380337
View directory record Official record
Conditions
Rectal Cancer
Interventions
FOLFOXIRI, FOLFOX regimen, XELOX, IMRT
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 18, 2026, 7:34 AM EDT
Terminated Phase 1 Interventional

Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

NCT01312376
View directory record Official record
Conditions
Ovarian Carcinoma, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
OC-DC vaccine, Bevacizumab, cyclophosphamide 300 mg/m2/d for 3 days, fludarabine 30 mg/m2/d for 3 days, ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells
Biological · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 18, 2026, 7:34 AM EDT
Active, not recruiting Phase 2 Interventional

Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer

NCT03624660
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
HR-A, HR-B
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 18, 2026, 7:34 AM EDT